UCB Governance
The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.
UCB SA/NV has adopted the 2020 edition of the Belgian Code of Corporate Governance as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB SA/NV, as a listed company, has adopted a Corporate Governance Charter and a Code of Conduct, including a Dealing Code.
The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term sustainable value for all the Company’s stakeholders. It will be continuously updated as required.
Articles of Association
Special Reports of the Board
Remuneration Policy 2023
Related Press Releases
Corporate governance charter
![](/sites/default/files/2021-07/280_Governance_-_Governance_charter.png)
Dealing code
![](/sites/default/files/2021-07/280_Governance_-_Dealing_code.png)
Code of conduct
![](/sites/default/files/2022-05/Code-of-conduct_Thumbnail_May-2022.png)
Board of Directors
To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.
![](/sites/default/files/2022-02/board-of-directors-_0.png)
the Audit Committee
The Audit Committee assists the Board in its responsibility of monitoring the management of UCB and the UCB Group as a whole.
3 members (67% independent):
- Rodolfo J. Savitzky (Chair & Independent Director)
- Maëlys Castella (Independent Director)
- Cédric van Rijckevorsel (Director)
the Governance, Nomination and Compensation Committee (GNCC)
The Governance, Remuneration and Nomination Committee (GNCC) ensures that the appointment and re-election process is organized objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers.
5 members (80% independent):
- Kay Davies (Chair & Independent Director)
- Charles-Antoine Janssen (Director)
- Pierre Gurdjian (Independent Director)
- Nefertiti Greene (Independent Director)
- Ulf Wiinberg (Independent Director)
the Scientific Committee
The Scientific Committee assists the Board when reviewing the quality of UCB’s R&D science and its competitive standing. It assesses the strategy proposed by UCB’s management in R&D matters and communicates its recommendations to the Board.
3 members (100% independent):
- Kay Davies (Independent Director)
- Susan Gasser (Independent Director)
- Dolca Thomas (Independent Director)
Composition
(Updated: April 2024)
14 Members
10 Independent Directors (71%)
8 Nationalities
6 Women (43%)
4-Year Mandate
Age Limit: 70
Jonathan Peacock
![](/sites/default/files/2023-03/230323_Peacock-Jonathan_0.jpg)
Independent Director
Chair of the Board
Chair of the Audit Committee
First appointed in 2021
End of term in 2025
Charles-Antoine Janssen
![](/sites/default/files/2023-03/230323_Janssen-Charles-Antoine_0.jpg)
Director
Vice-chair of the Board
Member of the GNCC
First appointed in 2012
End of term in 2028
Jean-Christophe Tellier
![](/sites/default/files/2023-03/230323_Tellier-Jean-Christophe_0.jpg)
Executive Director
First appointed in 2014
End of term in 2026
Jan Berger
![](/sites/default/files/2023-03/230323_Berger-Jan_0.jpg)
Independent Director
First appointed in 2019
End of term in 2027
Maëlys Castella
![](/sites/default/files/2023-03/230323_Castella-Maelys_0.jpg)
Independent Director
Member of the Audit Committee
First appointed in 2023
End of term in 2027
Kay Davies
![](/sites/default/files/2023-03/230323_Davies-Kay_0.jpg)
Independent Director
Member of the Scientific Committee
Chair of the GNCC
First appointed in 2014
End of term in 2026
Pierre Gurdjian
![](/sites/default/files/2023-03/230323_Gurdjian-Pierre_1.jpg)
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Susan Gasser
![](/sites/default/files/2023-03/230323_Gasser-Susan_0.jpg)
Independent Director
Member of the Scientific Committee
First appointed in 2021
End of term in 2025
Cyril Janssen
![](/sites/default/files/2023-03/230323_Janssen-Cyril_0.jpg)
Director
First appointed in 2015
End of term in 2027
Cédric van Rijckevorsel
![](/sites/default/files/2023-03/230323_van-Rijckevorsel-Cedric_0.jpg)
Director
Member of the Audit Committee
First appointed in 2014
End of term in 2026
Ulf Wiinberg
![](/sites/default/files/2023-03/230323_Wiinberg-Ulf_0.jpg)
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Nefertiti Greene
![](/sites/default/files/2024-04/240315_nefertiti-greene.jpg)
Independent Director
Member of the GNCC
First appointed in 2024
End of term in 2028
Dolca Thomas
![](/sites/default/files/2024-04/240315_dolca-thomas.jpg)
Independent Director
Member of the Scientific Committee
First appointed in 2024
End of term in 2028
Rodolfo Savitzky
![](/sites/default/files/2024-04/240315_rodolfo_savitzky.jpg)
Independent Director
Chair of the Audit Committee
First appointed in 2024
End of term in 2028
Honorary directors
- Karel Boone, Honorary Chair
- Evelyn du Monceau, Honorary Chair
- Mark Eyskens, Honorary Chair
- Georges Jacobs de Hagen, Honorary Chair
- Daniel Janssen, Honorary Deputy Chair
- Gerhard Mayr, Honorary Chair
- Prince Lorenz of Belgium
- Alan Blinken
- Alice Dautry
- Arnoud de Pret
- Roch Doliveux
- Peter Fellner
- Guy Keutgen
- Jean-Pierre Kinet
- Tom McKillop
- Gaëtan van de Werve
- Jean-Louis Vanherweghem
- Bridget van Rijckevorsel
- Norman J. Ornstein
Executive Committee
We have adapted an organizational structure on four pillars around which we create value for each patient, centered by our focus and integrated across functional teams around different patient populations.
![](/sites/default/files/2024-02/FY23_Organization-Model.png)
Composition
(Updated: April 2024)
9 members
5 nationalities
5 women (55%)
Jean-Christophe Tellier
![](/sites/default/files/2023-05/230323_Tellier-Jean-Christophe.jpg)
Chief Executive Officer &
Chairman of the Executive Committee
Joined UCB in 2011
Appointed CEO in 2015
Emmanuel Caeymaex
![](/sites/default/files/2023-05/230505_Caeymaex-Emmanuel.jpg)
Executive Vice President
Chief Commercial Officer
Joined UCB in 1994
Appointed in 2015
Sandrine Dufour
![](/sites/default/files/2023-05/230505_Dufour-Sandrine.jpg)
Executive Vice President
Chief Financial Officer
Joined UCB in July 2020
Appointed in July 2020
Jean Luc Fleurial
![](/sites/default/files/2023-05/230505_Fleurial-Jean-Luc.jpg)
Executive Vice President
Chief Human Resources Officer
Joined UCB in 2017
Appointed in 2017
Fiona du Monceau
![](/sites/default/files/2024-04/20220727-ucb_portraits-194_1.jpg)
Executive Vice President
Patient Evidence
Joined UCB in 2024
Appointed in 2024
Kirsten Lund-Jurgensen
![](/sites/default/files/2023-05/230505_Lund-Jurgensen-Kirsten.jpg)
Executive Vice President
Supply & Technology Solutions
Joined UCB in 2019
Appointed in 2019
Alistair Henry
![](/sites/default/files/2024-04/alistair_henry.png)
Executive Vice President &
Chief Scientific Officer
Joined UCB in 2004
Appointed in 2024
Iris Loew-Friedrich
![](/sites/default/files/2024-04/20220727-ucb_portraits-053.jpg)
Executive Vice President &
Chief Medical Officer
Joined UCB in 2006
Appointed in 2008
Denelle J. Waynick Johnson
![](/sites/default/files/2023-05/230505_Waynick-Johnson-Denelle.jpg)
Executive Vice President &
General Counsel
Joined UCB in 2023
Appointed in 2023
Shareholders and Shareholder Meetings
Find out about UCB shareholders, their transparency notifications and our shareholder meetings on the dedicated webpage.